Bortezomib and dexamethasone for multiple myeloma: AST and LDH associated with overall survival
نویسنده
چکیده
Takayoshi Kiba ([email protected]), Takuo Ito([email protected]), Toshihisa Nakashima([email protected]), Yoshiko Okikawa([email protected]), Miki Kido([email protected]), Akiko Kimura([email protected]), Keita Kameda([email protected]), Fumiaki Miyamae([email protected]), Suzuko Tanaka([email protected]), Misao Atsumi([email protected]), Yoko Sumitani([email protected]), Yoshimi Shitakubo([email protected]), Hiromasa Niimi([email protected])
منابع مشابه
Characteristics and outcomes of patients with multiple myeloma : Data from a developing country
Background: Multiple myeloma (MM) is a plasma cell disorder characterized by presence of monoclonal protein in serum or urine or both, increased bone marrow plasma cells, osteolytic lesion, hypercalcemia, and anemia. Several combination regimens are commonly recommended for treatment of multiple myeloma. The present study aimed at determining the characteristics and outcomes of patients with mu...
متن کاملCarfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib-resistant patients, as may provide much longer overall survival than previously reported treatments.
متن کاملChanges in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
Little is known about the impact of multiple myeloma (MM) treatment on uninvolved immunoglobulins (Ig). We identified 448 patients who received high-dose dexamethasone (HD-DEX), lenalidomide and dexamethasone (RD), bortezomib and dexamethasone (VD), bortezomib, cyclophosphamide and dexamethasone (VCD) or bortezomib, lenalidomide and dexamethasone (VRD) for newly diagnosed MM at our institution ...
متن کاملBortezomib: the evidence of its clinical impact in multiple myeloma
INTRODUCTION Multiple myeloma is a relatively common and incurable form of hematologic malignancy for which there is currently no single standard therapy. Bortezomib inhibits the 20S proteasome involved in the degradation of intracellular proteins, induces apoptosis, reverses drug resistance in multiple myeloma cells, and influences their microenvironment by blocking cytokine circuits, cell adh...
متن کاملBortezomib or high-dose dexamethasone for relapsed multiple myeloma.
BACKGROUND This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had received one to three previous therapies. METHODS We randomly assigned 669 patients with relapsed myeloma to receive either an intravenous bolus of bortezomib (1.3 mg per square meter of body-surface area) on days 1, 4, 8, and 11 for eight three-week cycles, followed by tr...
متن کامل